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ABSTRAK
Penyakit Graves atau Graves’ disease merupakan penyakit autoimun yang mengenai kelenjar tiroid. Penyakit 
Graves merupakan penyebab tersering hipertiroidisme dan tirotoksikosis. Pemahaman mengenai patofisiologi 
penyakit, strategi diagnosis dan terapi, serta pencegahan relaps penting diketahui oleh semua klinisi khususnya 
spesialis penyakit dalam untuk memberikan manajemen yang optimal dan komprehensif bagi pasien penyakit 
Graves. Artikel ini memberikan poin-poin klinis untuk manajemen pasien dengan penyakit Graves berdasarkan 
review dan guidelines terbaru dari American Thyroid Association (ATA), European Thyroid Association (ETA), 
dan Japan Thyroid Association/ Japan Endocrine Society.
Kata kunci: penyakit Graves, tiroid, American Thyroid Association (ATA), European Thyroid Association 
(ETA), Japan Thyroid Association/ Japan Endocrine Society.
ABSTRACT
Graves’ disease (GD) is an autoimmune disorder which affect thyroid gland. Graves’ disease is the most 
common cause of hyperthyroidism and thyrotoxicosis. Understanding of disease pathophysiology, diagnostic 
and treatment strategies, and prevention of disease relapse are important for all clinicians especially internal 
medicine specialist to give optimal and comprehensive management for GD patients. This article highlights 
clinical points to treat GD patients from reviews and latest guidelines from American Thyroid Association (ATA), 
European Thyroid Association (ETA), and Japan Thyroid Association/ Japan Endocrine Society.
Keywords: Graves’ disease, thyroid, American Thyroid Association (ATA), European Thyroid Association 
(ETA), Japan Thyroid Association/ Japan Endocrine Society.
INTRODUCTION
Graves’ disease (GD) was originally described 
by the Irish physician, Robert James Graves 
in 1835. Graves’ disease includes signs and 
symptoms consisting of goiter, palpitation 
(tachycardia), and exophtalmus.1 Graves’ disease 
represents a part of more extensive autoimmune 
thyroid disease (AITD), leading to dysfunction of 
multiple organs, marked by the presence of thyroid 
stimulating hormone receptor antibody (TRAb).2 
Moreover, GD is different from any other 
autoimmune diseases, because it does not correlate 
with hypo-function, but - on the contrary - causes 
hyper-function of the organ (thyroid). Hyper-
function of the thyroid can lead to thyrotoxicosis 
and enlarged of the thyroid gland.3
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Prevalence of GD is relatively high compared 
to other hyperthyroidism causes. According to 
Weetman, from all hyperthyroidism cases, there 
are 60-80% cases which diagnosed with Graves’ 
disease. These findings are affected by regional 
factors especially iodine intake.3 Study at Cipto 
Mangunkusumo General Hospital in 2004 showed 
that the prevalence of hyperthyroidism cases from 
all thyroid problems were 21%.4
Knowing the fact that GD is an autoimmune 
disease, relapsing cases are common which can 
lead to prolonged time to treat the disease. Like 
any other autoimmune diseases, remission time 
of this disease cannot be determined. From this 
statement, we need to understand the concept 
of treatment concerning the pathophysiology 
of Graves’ disease. The aim of this review is to 
refresh clinical management points of GD from 
reviews and the latest guidelines (American 
Thyroid Association, European Thyroid 
Association, and Japan Thyroid Association/
Japan Endocrine Society).  
DIAGNOSIS
Diagnosis of Graves’ disease (GD) made 
based on signs, symptoms, and the result of the 
ancillary laboratory tests. Manifestation of this 
disease is the Merseburger triad that consists of 
thyrotoxicosis, diffuse goiter, and ophthalmopathy 
(orbitopathy). Other than those, dermopathy is 
also one of the manifestation of Graves’ although 
it has low prevalence.5
Manifestation of Graves’ are various, from 
mild to full blown. The common signs and 
symptoms of Graves are shown in Table 1.
Clinically, GD can be diagnosed based 
on the signs and symptoms of thyrotoxicosis. 
Although the diagnosis can be determined, 
treatment should be based on the result of the 
laboratory test (TSHs and free T4) to confirm the 
diagnosis and as a basis for treatment evaluation. 
The same course of action (checking laboratory 
values) is applied if the signs and symptoms of 
thyrotoxicosis does not appear or unclear. Based 
on low concentration of TSHs and high fT4 
concentration (depending on the reagents), the 
diagnosis of GD can be determined.
T3 examination is needed if physical 
examination leads to GD, but the laboratory 
result shows low TSHs concentration with 
normal fT4 value. When there is a doubt on 
the signs and symptoms of thyrotoxicosis, 
absence of visible enlargement of thyroid gland, 
scintigraphy (thyroid nuclear scan) can be done. 
Even after doing all of those tests, it is not 
uncommon for the diagnosis of GD to still be 
undetermined. When that happen, TRAb test is 
recommended. The concentration of TRAb can 
be used for diagnostic purpose and evaluation of 
treatment and remission.6
TREATMENT
The goal treatment of GD is to control and 
correct the condition based on the pathophysiology 
of Graves’ disease (antigen-antibody reactions in 
the thyroid glands). Glucocorticoid can reduce 
the conversion of T4 to T3 and lower the thyroid 
hormone with unknown mechanism. Considering 
the long duration of GD treatment, prolonged use 
of glucocorticoid may lead to more harm than 
benefits, therefore it is not usually used as first 
line treatment.7
Modalities for GD treatment consists of anti-
thyroid drugs, surgery, and radioactive iodine 
treatment (RAI) with iodium-131 (131I). The 
choice of treatment is based on several factors; 
severity of the thyrotoxicosis, age, size of the 
goiter, availability of the modalities, response of 
the treatments, and other comorbidities.7
Anti-thyroid Drugs
There are 2 types of anti-thyroid drugs which 
are propylthiouracil (PTU) and methimazole. 
PTU works by inhibiting the organification of 
iodides and coupling process, while methimazole 
inhibits the oxidation of iodine in the thyroid 
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gland. If one of these drugs used as a primary 
therapy, it should be given for at least 12-18 
months, and will be stopped as the concentrations 
of TSH and TRAb reach normal value. Azizi, et 
al8 reported that prolonged use of anti-thyroid 
drugs is effective and safe, especially for adults. 
Therefore, anti-thyroid drugs is the first choice 
of treatment in Graves’ disease.
Indication of oral anti-thyroid drugs: a). 
High possibility of remission (woman, mild 
clinical manifestation, mild goiter, negative or 
low TRAb); b). Pregnant woman with GD; c). 
Elderly, or comorbidity with other diseases that 
increases risk of surgery or short life expectancy; 
d). Patients in nursing home or other health care 
facilities, unable to follow the regulation of 
radioactive iodine therapy; e). History of surgery 
or neck radiation; f). Limited thyroid surgeon 
in the area; g). Moderate or severe Graves’ 
ophthalmopathy; h). Immediate needs to lower 
thyroid (fT4) level.7
Surgery
Near total and total thyroidectomy are the 
main types of surgery in hyperthyroidism cases.
Indication of surgery: a). Woman planning 
on pregnancy in less than 6 months; b). 
Enlarged goiter and compression of other 
organs surrounding thyroid gland; c). Low 
uptake on the thyroid scanning; d). Malignant 
or suspicious/indeterminate on the cytology 
examination; e). Thyroid nodules larger than 
4cm, or nonfuctioning or hypofunctioning on 
the thyroid scanning; f). Hyperparathyroidism; 
g). High TRAb level (difficult of treat with anti-
thyroid drugs); h). Moderate or severe active 
Graves’ ophthalmopathy.7,9
Risks of thyroidectomy surgery are bleeding, 
paralysis of the vocal cord, and hypocalcemia. 
These risks can be minimalized by trained and 
experienced thyroid of head-neck surgeon.9
Radioactive Iodine Therapy (RAI)
RAI can be applied in patients with risks 
of anti-thyroid drugs side effect and with 
comorbidities.
Indication of RAI therapy: a). Woman 
planning on pregnancy more than 6 months after 
RAI therapy; b). Comorbidities that may increase 
surgery risks; c). History of surgery or external 
neck radiation; d). Limited thyroid surgeon in 
the area; e). Contraindicated for anti-thyroid 
drugs or failure to reach euthyroidism with 
drugs; f). Patients with periodic thyrotoxicosis 
hypokalemic paralysis, right heart failure caused 
by pulmonary hypertension or congestive heart 
failure.7
Other than those modalities, inhibition 
of beta adrenergic is recommended for all 
thyrotoxicosis patients with clear manifestations, 
especially in elderly, those with pulse of > 90x/
minute, or any other cardiovascular diseases. 
Benefits of beta blocker are:
a. Decrease the hyper adrenergic-thyrotoxicosis 
signs and symptoms (palpitation, tremor, 
anxiety, and heat intolerant) rapidly before 
thyroid hormone reaches normal level.
b. Prevent the episodes of hypokalemic periodic 
paralysis.
c. Inhibit the conversion of T4 to T3 in the 
peripheral with high dose propranolol.
d. Preparation for surgery.
RELAPSE
As an autoimmune disease, Graves’ disease 
(GD) is a ‘relapse and remission’ disease. Graves’ 
disease patients have a chance to experience 
relapse after stopping anti-thyroid drugs. These 
days, many explanation and evidences about 
relapse of GD published in many scientific forum 
and review. Systematic review and meta-analysis 
from Struja, et al.10 showed that occurrence of 
ophthalmopathy, smoking, thyroid volume and 
goiter size, fT4, fT3, TRAb, and TBII value 
were associated with disease relapse, while male 
sex, age, and initial T4 were not associated with 
relapse. Study from Eliana F, et al.11 in Indonesian 
population revealed that besides family history, age 
at diagnosis, second degree of ophthalmopathy, 
enlarged thyroid gland which exceeded the 
lateral edge of the sternocleidomastoid muscles 
and duration of remission period; genetic 
polymorphisms of CTLA-4 gene, TSHR gene, 
and number of regulatory T cells and TRAb levels 
play a role as risk factors for relapse in patients 
with Graves’ disease.
Titration of anti-thyroid drugs regimen 
for 12-18 months is an optimal strategy for 
preventing relapse in GD patients. It is not 
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recommended to administer levothyroxine after 
successful anti-thyroid drugs treatment. Studies 
give evidences to add immunosuppressive agents 
to decrease the recurrence rate after anti-thyroid 
drugs. Consumption of Vitamin D, selenium, 
and stop smoking may also beneficial to prevent 
relapse in GD patients.12
THYROID STORM
The most severe and acute condition of 
GD is thyroid storm or thyroid crisis which 
is an endocrine emergency. The diagnosis of 
thyroid storm is made by clinical observation 
and systemic decompensation of thyrotoxicosis 
with a known precipitating factors or triggering 
illnesses. Since the mortality rate is very high, 
early suspicion, prompt diagnosis, and intensive 
management are needed by clinician in primary 
care and hospital.13
For decades, clinician used Burch and 
Wartofsky clinical scoring consists of temperature, 
central nervous system problems, heart rate and 
rhythm, congestive heart failure, gastrointestinal 
problems, and presence of precipitant history.7 
These scoring system is very sensitive so 
that all cases with suspicious condition like 
thyrotoxicosis and other comorbidity (infection, 
heart condition, or post-operative patients) can 
be classified as thyroid storm. In 2016, Japan 
Thyroid Association and Japan Endocrine 
Society published new guideline for diagnosis 
and treatment of thyroid storm. This guideline is 
very comprehensive and clear to guide clinician 
for making diagnosis of thyroid storm.
In Japanese guideline, for making diagnosis 
of thyroid storm there must be presence of 
thyrotoxicosis with elevated level of fT3 or 
fT4 as prerequisite condition. Definite thyroid 
storm is a condition when thyrotoxicosis 
and at least one central nervous system 
manifestation and fever, tachycardia, congestive 
heart failure, of GI/hepatic manifestations, or 
thyrotoxicosis and at least three combinations 
of fever, tachycardia, congestive heart failure, 
or GI/hepatic manifestations. Suspected thyroid 
storm is a condition when thyrotoxicosis and 
combination of two of the following: fever, 
tachycardia, congestive heart failure, of GI/
hepatic manifestations, or patients who met 
diagnosis of definite thyroid storm condition 
except that serum fT3 or fT4 level are not 
available.13 These diagnostic criteria are more 
simple and clear than previous clinical score.
The present guideline also includes 
15 recommendations for the treatment of 
thyrotoxicosis and systemic organ dysfunction 
affected by thyroid storm, such as central nervous 
system, cardiovascular system, GI/hepatic tract, 
admission criteria for intensive care unit. They 
also explain preventive approaches to thyroid 
storm, roles of definitive and supportive therapy 
of thyroid storm. Treatment of thyroid storm 
includes anti-thyroid drugs (propylthiouracil 
or methimazole), drugs which blocked thyroid 
hormones secretion such as sodium iodide, 
potassium iodide and lugol solution, beta 
blockers (esmolol, propranolol, metoprolol), 
intravenous fluid resuscitation, glucocorticoid 
(hydrocortisone, methylprednisolone, or 
dexamethasone), and treat the precipitant 
condition (infection, metabolic or post-operative 
stress, etc).13
GRAVES’ ORBITOPATHY
One special condition which always discussed 
and updated in many studies and guidelines 
of GD, hyperthyroidism, or thyrotoxicosis 
is Graves’ orbitopathy (GO) or Graves’ 
ophthalmopathy or thyroid eye disease (TED) 
or thyroid associated ophthalmopathy (TAO). 
This condition needs special attention and close 
collaboration with ophthalmologist (especially 
consultant in oculoplastic surgery or thyroid eye 
disease specialist). The latest guideline focusing 
on Graves’ orbitopathy is the 2016 European 
Thyroid Association/EUGOGO (European 
Group on Graves’ Orbitopathy) guidelines for 
management of Graves’ orbitopathy.14 In this 
guideline, clearly stated all diagnostic modalities 
to diagnose and comprehensive treatment of GO. 
The guideline also stressed about quality of life 
in patients with GO and complete assessment of 
GO. Figure 1 is summary treatment algorithm 
for GO patients.
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CONCLUSION
Graves’ disease (GD) is an organ-specific 
autoimmune disorder that is marked by findings 
of TRAb, with manifestation of diffuse goiter, 
thyrotoxicosis, and ophthalmopathy. The 
diagnosis is determined by signs and symptoms 
of thyrotoxicosis, and confirmed by low TSHs 
level and high thyroxin (fT4) level. If needed, 
TRAb examination can be done and diagnosis 
is confirmed by positive result.
There are three modalities used to treat GD; 
anti-thyroid drugs, surgery, and RAI therapy. 
Choice of modality depends on the severity of the 
thyrotoxicosis, size of goiter, age, availability of 
the anti-thyroid drugs, response to the treatment, 
and comorbidities. If drugs were used as the 
primary therapy, it should be given for at least 
12-18 months. If surgery is chosen for primary 
therapy, near total or total thyroidectomy is the 
choice of surgery. RAI therapy can be done if 
there are side effects of the anti-thyroid drugs, 
history of neck surgery or external neck radiation. 
Beta blocker can be used to reduce signs and 
symptoms of thyrotoxicosis and to inhibit the 
conversion of T4 to T3 in the peripheral organs.
Relapse is common in the treatment 
course. Risk factors for relapse are presence of 
ophthalmopathy, smoking, high level of thyroid 
hormones and antibodies, large thyroid volume, 
and genetic polymorphisms variations. Titration 
of anti-thyroid drugs for more than 12 months, 
immunosuppresive agents, vitamin D, selenium, 
and stop smoking are beneficial to prevent 
relapse in GD patients.
Thyroid storm and Graves’ orbitopathy 
are two conditions in GD patients which need 
collaborative and special treatment. Two latest 
guidelines from Japan Thyroid Association 
and European Thyroid Association/EUGOGO 
explained comprehensive management of thyroid 
storm and Graves’ orbitopathy respectively.
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